GlassScriptPhysician profile
Jeffrey Winebrenner
NPI 1184695629
$1,557.47
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.27 · 2022: $559 · 2023: $939 · 2024: $14.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $953.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $272.27 | 2022-2024 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $207.32 | 2022-2023 | Rybelsus, Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $185.10 | 2021-2023 | Xifaxan |
| Axsome Therapeutics, INC. | $119.62 | 2022-2023 | Sunosi |
| Merck Sharp & Dohme LLC | $87.96 | 2022-2023 | Verquvo, Steglatro, Belsomra |
| Daiichi Sankyo INC. | $80.29 | 2023 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $75.25 | 2022-2023 | Farxiga, Breztri |
| Novartis Pharmaceuticals Corporation | $67.03 | 2022-2023 | |
| Pfizer INC. | $65.12 | 2023 | |
| Idorsia Pharmaceuticals US INC | $60.55 | 2023 | Quviviq |
| Lilly USA, LLC | $47.78 | 2022-2023 | Mounjaro |
| Astellas Pharma US INC | $40.79 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $39.32 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $36.54 | 2023 | |
| Glaxosmithkline, LLC. | $33.29 | 2023 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.28 | 2023 | Jardiance |
| Mylan Specialty L.P. | $26.02 | 2022-2023 | Yupelri |
| Biohaven Pharmaceutical Holding Company LTD. | $16.48 | 2022 | |
| Almatica Pharma LLC | $14.86 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.76 | 2023 | Ajovy |
| Bayer Healthcare Pharmaceuticals INC. | $13.48 | 2022 | |
| Dexcom, INC. | $13.41 | 2023 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $12.95 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Winebrenner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.